DRAXIS to Host Analyst and Investor Day



    MISSISSAUGA, ON, March 19 /CNW/ - DRAXIS Health Inc. (TSX: DAX) (Nasdaq:  
DRAX) will host invited guests at an Analyst and Investor Day at the DRAXIS
manufacturing facility in Kirkland, Quebec on March 22, 2007. Dr. Martin
Barkin, President and Chief Executive Officer and the senior management team
will present on Thursday March 22, starting at 10:45 a.m. ET.
    A live audio webcast of the event, including presentation slides, will be
accessible through a link on the home page of the DRAXIS website at
www.draxis.com. An archived version of the webcast will be available on the
Company's website for 30 days following the event.

    About DRAXIS Health Inc.

    DRAXIS Health, through its wholly owned operating subsidiary, DRAXIS
Specialty Pharmaceuticals Inc., provides products in three categories: sterile
products, non-sterile products and radiopharmaceuticals. Sterile products
include liquid and freeze-dried (lyophilized) injectables plus sterile
ointments and creams. Non-sterile products are produced as solid oral and
semi-solid dosage forms. Radiopharmaceuticals are used for both therapeutic
and diagnostic molecular imaging applications. Pharmaceutical contract
manufacturing services are provided through the DRAXIS Pharma division and
radiopharmaceuticals are developed, produced, and sold through the DRAXIMAGE
division. DRAXIS employs approximately 500 staff in its Montreal facility.
    For additional information please visit www.draxis.com.

    Caution Concerning Forward-Looking Statements

    This news release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended (the "Securities
Act"), and as contemplated under the Private Securities Litigation Reform Act
of 1995 and other applicable securities legislation. These statements are not
guarantees of future performance. By their nature, forward-looking statements
involve numerous assumptions, known and unknown risks, uncertainties and other
factors that may cause the actual results or performance of the Company to be
materially different from such statements or from any future results or
performance implied thereby. Factors that could cause the Company's results or
performance to differ materially from a conclusion, forecast or projection in
the forward-looking statements include, but are not limited to:

    
    -   the achievement of desired clinical trial results related to the
        Company's pipeline products;

    -   timely regulatory approval of the Company's products;

    -   the ability to comply with regulatory requirements applicable to the
        manufacture and marketing of the Company's products;

    -   the Company's ability to obtain and enforce effective patents;

    -   the non-infringement of third party patents or proprietary rights by
        the Company and its products;

    -   factors beyond our control that could cause interruptions in our
        operations in our single manufacturing facility (including, without
        limitation, material equipment breakdowns);

    -   reimbursement policies related to health care;

    -   the establishment and maintenance of strategic collaborative and
        commercial relationships;

    -   the Company's dependence on a small number of key customers;

    -   the disclosure of confidential information by our collaborators,
        employees or consultants;

    -   the preservation of healthy working relationships with the Company's
        union and employees;

    -   the Company's ability to grow the business;

    -   the fluctuation of our financial results and exchange and interest
        rate fluctuations;

    -   the adaptation to changing technologies;

    -   the loss of key personnel;

    -   the avoidance of product liability claims;

    -   the loss incurred if current lawsuits against us succeed;

    -   the volatility of the price of our common shares;

    -   market acceptance of the Company's products; and

    -   the risks described in "Item 3. Key Information - Risk Factors" in
        the Annual Report Form 20-F filed by the Company with the United
        States Securities and Exchange Commission and which is also filed as
        the Company's Annual Information Form with Canadian securities
        regulators.
    

    For additional information with respect to certain of these and other
factors, and relating to the Company generally, reference should be made to
the Company's most recent filings with the United States Securities and
Exchange Commission (available on EDGAR at www.sec.gov) and the filings made
by the Company with Canadian securities regulators (available on SEDAR at
www.sedar.com). The forward-looking statements contained in this new release
represent the Company's expectations as at March 19, 2007. Unless otherwise
required by applicable securities laws, the Company disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.

    %SEDAR: 00004049E




For further information:

For further information: Jerry Ormiston, Executive Director, Investor
Relations, DRAXIS Health Inc., Phone: 1-877-441-1984

Organization Profile

DRAXIS SPECIALTY PHARMACEUTICALS INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890